PharmaCorp Rx Inc. to Present at Planet MicroCap Toronto 2026 Conference
PharmaCorp Rx Inc. announced that its senior management team will deliver a presentation at the upcoming Planet MicroCap Toronto 2026 Conference.
Stocks · News reference
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5
RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $25 to $36.5.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Top 3 Health Care Stocks That May Fall Off A Cliff In October
Option Care Health, Pacira Biosciences and HealthStream show overbought RSI levels above 83, warning momentum-focused investors.
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
Viatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion in cash at $36.50 per share, expected to close by end of 2026. The acquisition adds two marketed pain therapies (Exparel and Zilretta) generating $350.5 million in H1 2026 sales, plus a mid-stage gene therapy candidate (PCRX-201) for knee osteoarthritis. The deal is expected to be immediately accretive to Viatris' financial metrics and strengthen its non-opioid pain management portfolio.
Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5
Truist Securities analyst Anish Nikhanj downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold and raises the price target from $31 to $36.5.